HRP20190939T1 - Monoklonska antitijela za upotrebu u dijagnozi i terapiji raka i autoimunih bolesti - Google Patents

Monoklonska antitijela za upotrebu u dijagnozi i terapiji raka i autoimunih bolesti Download PDF

Info

Publication number
HRP20190939T1
HRP20190939T1 HRP20190939TT HRP20190939T HRP20190939T1 HR P20190939 T1 HRP20190939 T1 HR P20190939T1 HR P20190939T T HRP20190939T T HR P20190939TT HR P20190939 T HRP20190939 T HR P20190939T HR P20190939 T1 HRP20190939 T1 HR P20190939T1
Authority
HR
Croatia
Prior art keywords
antibody
seq
heavy chain
light chain
tumor
Prior art date
Application number
HRP20190939TT
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey Molldrem
Anna Sergeeva
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of HRP20190939T1 publication Critical patent/HRP20190939T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
HRP20190939TT 2012-07-10 2019-05-21 Monoklonska antitijela za upotrebu u dijagnozi i terapiji raka i autoimunih bolesti HRP20190939T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261669967P 2012-07-10 2012-07-10
US201261702916P 2012-09-19 2012-09-19
EP16152641.3A EP3088421B1 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

Publications (1)

Publication Number Publication Date
HRP20190939T1 true HRP20190939T1 (hr) 2019-07-26

Family

ID=49916655

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190939TT HRP20190939T1 (hr) 2012-07-10 2019-05-21 Monoklonska antitijela za upotrebu u dijagnozi i terapiji raka i autoimunih bolesti

Country Status (25)

Country Link
US (2) US9926380B2 (enExample)
EP (2) EP2872174A2 (enExample)
JP (1) JP6336696B2 (enExample)
KR (1) KR102049222B1 (enExample)
CN (1) CN104540522B (enExample)
AU (1) AU2013288982B2 (enExample)
CA (1) CA2883056C (enExample)
CY (1) CY1121743T1 (enExample)
DK (1) DK3088421T3 (enExample)
EA (1) EA034033B1 (enExample)
ES (1) ES2720291T3 (enExample)
HR (1) HRP20190939T1 (enExample)
HU (1) HUE043443T2 (enExample)
IL (1) IL236664B (enExample)
IN (1) IN2015DN00263A (enExample)
LT (1) LT3088421T (enExample)
MX (1) MX360984B (enExample)
PH (1) PH12015500074B1 (enExample)
PL (1) PL3088421T3 (enExample)
PT (1) PT3088421T (enExample)
RS (1) RS58755B1 (enExample)
SI (1) SI3088421T1 (enExample)
UA (1) UA114108C2 (enExample)
WO (1) WO2014011489A2 (enExample)
ZA (1) ZA201500247B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
SG11201608557UA (en) * 2014-04-16 2016-11-29 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
KR20180108567A (ko) 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
IL270142B2 (en) 2017-04-27 2025-05-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
MX2019015053A (es) 2017-06-14 2020-02-13 Adicet Bio Inc Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos.
CN108611322B (zh) * 2018-05-09 2020-02-11 邹畅 乳腺癌循环肿瘤细胞系ctc-3、培养基及ctc-3的建立方法和应用
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2021202798A1 (en) * 2020-04-02 2021-10-07 The United States Of America As Represented By The Secretary Of The Navy Antigen binding proteins to class 5 etec adhesins
CA3227281A1 (en) * 2021-07-26 2023-02-02 Michael H. Cardone Methods and compositions related to mcl-1 and bim heterodimer antibodies
WO2024102497A2 (en) * 2022-11-11 2024-05-16 Renovorx, Inc. Methods and apparatuses for delivering an agent through the vasa vasorum
WO2025049921A1 (en) * 2023-08-30 2025-03-06 University Of Louisville Research Foundation, Inc. Methods for single molecule resolution of near full-length immunoglobulin heavy and light chain repertoires

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4843092A (en) 1986-04-25 1989-06-27 Hitoshi Shichi Immunosuppressive agent
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
FR2658197B1 (fr) 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6534633B1 (en) 1998-10-21 2003-03-18 Altor Bioscience Corporation Polyspecific binding molecules and uses thereof
JP4447456B2 (ja) 2001-06-05 2010-04-07 アルトール バイオサイエンス コーポレーション Ｐ５３結合ｔ細胞受容体分子とその使用
US20100291102A1 (en) 2001-07-02 2010-11-18 Ice Biologics Limited Therapeutic Agent
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
JPWO2004033499A1 (ja) 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
US20060167230A1 (en) 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
WO2005056603A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US20060045884A1 (en) 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
EP1876236B9 (en) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
JPWO2006123724A1 (ja) 2005-05-18 2008-12-25 国立大学法人徳島大学 抗ｈｌａ抗体を利用した新規医薬品
CA2662798A1 (en) 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
TW200808351A (en) 2006-07-13 2008-02-16 Chugai Pharmaceutical Co Ltd Cell death-inducing agents
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
WO2010065962A2 (en) 2008-12-05 2010-06-10 The Board Of Regents Of The University Of Texas System Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies

Also Published As

Publication number Publication date
CA2883056C (en) 2020-11-10
US20150191546A1 (en) 2015-07-09
ES2720291T3 (es) 2019-07-19
HK1208168A1 (en) 2016-02-26
AU2013288982A1 (en) 2015-01-29
MX360984B (es) 2018-11-22
CN104540522A (zh) 2015-04-22
AU2013288982A2 (en) 2016-01-14
KR20150039774A (ko) 2015-04-13
LT3088421T (lt) 2019-04-10
KR102049222B1 (ko) 2019-11-29
PT3088421T (pt) 2019-05-10
EA201590187A1 (ru) 2015-06-30
MX2015000450A (es) 2015-07-14
WO2014011489A3 (en) 2014-03-13
RS58755B1 (sr) 2019-06-28
PL3088421T3 (pl) 2019-08-30
ZA201500247B (en) 2023-04-26
EP2872174A2 (en) 2015-05-20
CY1121743T1 (el) 2020-07-31
US20180371106A1 (en) 2018-12-27
JP2015530359A (ja) 2015-10-15
AU2013288982B2 (en) 2018-04-26
US11192958B2 (en) 2021-12-07
PH12015500074A1 (en) 2015-03-02
US9926380B2 (en) 2018-03-27
CA2883056A1 (en) 2014-01-16
PH12015500074B1 (en) 2015-03-02
IL236664A0 (en) 2015-02-26
EP3088421B1 (en) 2019-02-27
UA114108C2 (uk) 2017-04-25
IL236664B (en) 2020-01-30
IN2015DN00263A (enExample) 2015-06-12
WO2014011489A8 (en) 2015-02-19
HUE043443T2 (hu) 2019-08-28
DK3088421T3 (da) 2019-05-13
EA034033B1 (ru) 2019-12-20
EP3088421A1 (en) 2016-11-02
CN104540522B (zh) 2018-05-01
WO2014011489A2 (en) 2014-01-16
JP6336696B2 (ja) 2018-06-06
SI3088421T1 (sl) 2019-04-30

Similar Documents

Publication Publication Date Title
HRP20190939T1 (hr) Monoklonska antitijela za upotrebu u dijagnozi i terapiji raka i autoimunih bolesti
US12409233B2 (en) Anti-PD-L1 single-domain antibody and derivatives and use thereof
ES2899036T3 (es) Nanocuerpo anti-PD-L1 y su uso
KR102344129B1 (ko) 메디토프를 위한 단일클론 항체 프레임워크 결합 계면, 메디토프 전달 시스템 및 이의 사용 방법
ES2595238T3 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial humano de tipo 2
JP2021502104A5 (enExample)
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
CN109575140A (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
CA3054615C (en) Improved anti-vegfr-2 monoclonal antibody
RU2020127887A (ru) Полипептиды транспозазы и их применение
HRP20192347T1 (hr) Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora
ES2689299T3 (es) Anticuerpo humano anti-receptor del factor de crecimiento epidérmico humano y gen codificante y aplicación del mismo
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2015530359A5 (enExample)
ES3037019T3 (en) Anti-cd25 antibody and application thereof
JP2008508858A5 (enExample)
HRP20180917T1 (hr) Novi fragmenti protutijela, pripravci i njihova upotreba
US20230391893A1 (en) Antibody-like protein and use thereof
WO2017114204A1 (zh) 一种抗足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途
JPWO2020058285A5 (enExample)
CN110872356B (zh) 双特异性抗体及其使用方法
CN116284386A (zh) 一种新型pd1单域抗体的开发
CN119431586B (zh) 一种结合Trop2的纳米抗体、嵌合抗原受体及其应用
KR102846816B1 (ko) Ct83 항원에 대한 인간 단클론 항체 및 이의 용도
US20250345451A1 (en) Anti-pd-l1 single-domain antibody and derivatives and use thereof